- Home
- EW
as 12-24-2024 1:36pm EST
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 42.5B | IPO Year: | 2000 |
| Target Price: | $79.40 | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.89 | EPS Growth: | 193.69 |
| 52 Week Low/High: | $58.93 - $96.12 | Next Earning Date: | 02-04-2025 |
| Revenue: | $6,314,900,000 | Revenue Growth: | 24.02% |
| Revenue Growth (this year): | -0.86% | Revenue Growth (next year): | 0.91% |
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ullem Scott B. | EW | CVP, Chief Financial Officer | Dec 9 '24 | Sell | $71.68 | 11,250 | $806,405.63 | 30,561 | |
| Chopra Daveen | EW | CVP, TMTT | Dec 6 '24 | Sell | $73.27 | 1,750 | $128,222.68 | 27,583 |
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
Zacks
a day ago
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
Insider Monkey
4 days ago
Jim Cramer: Is Edwards Lifesciences (EW) Poised for a Comeback?
Zacks
4 days ago
Is the Options Market Predicting a Spike in Edwards (EW) Stock?
MedTech Dive
4 days ago
CMS proposes Medicare coverage for transcatheter tricuspid replacement
MT Newswires
6 days ago
Baird Adjusts Edwards Lifesciences Price Target to $70 From $68, Maintains Neutral Rating
Simply Wall St.
6 days ago
Undervalued Small Caps With Insider Action To Watch In December 2024
Argus Research
7 days ago
EW: Raising target price to $65.00
MT Newswires
8 days ago
BofA Securities Upgrades Edwards Lifesciences to Buy From Neutral, Price Target is $90
Compare EW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.